News
-
-
PRESS RELEASE
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology -
-
PRESS RELEASE
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025 -
-
PRESS RELEASE
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Jaguar Health, Inc. announces virtual presentation and investor webcast dates. Company to file annual report on March 31, 2025. Lisa Conte to discuss upcoming developments -
-
PRESS RELEASE
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Jaguar Health, Inc. announced a private placement of convertible promissory notes to selected investors for working capital. H.C. Wainwright & Co. is the placement agent -
-
